Lessons learned from independent central review

References 

1. Food and Drug Administration. United States food and drug administration guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Rockville, MD: US Department of Health and Human Services; 2007.
2. Committee for Medicinal Products for Human Use. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) guideline on the evaluation of anticancer medicinal products in man. London, UK: European Medicines Agency; 2006.
3. United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 21-492 (oxaliplatin). Rockville, MD: US Department of Health and Human Services; 2002.
4. United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 21-923 (sorafenib tosylate). Rockville, MD: US Department of Health and Human Services; 2005.
5. United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 22-065 (ixabepilone). Rockville, MD: US Department of Health and Human Services; 2007.
6. United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 22-059 (lapatinib ditosylate). Rockville, MD: US Department of Health and Human Services; 2007.
7. United States Food and Drug Administration Center for Biologics Evaluation and Research. Approval package for BLA numbers 97-0260 and BLA Number 97-0244 (rituximab). Rockville, MD: US Department of Health and Human Services; 1997.
8. United States Food and Drug Administration. FDA clinical review of BLA 98-0369 (Herceptin^® trastuzumab (rhuMAb HER2)). FDA Center for Biologics Evaluation and Research; 1998.
9. United States Food and Drug Administration. FDA Briefing Document Oncology Drugs Advisory Committee meeting NDA 21801 (satraplatin). Rockville, MD: US Department of Health and Human Services; 2007.
10. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. JCO. 2007;(November):5210–5217
11. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. JCO. 2007;(November):5180–5186
12. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. JCO. 2007;(August):3407–3414
13. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. JCO. 2007;(June):2171–2177
14. Ghassan KA, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. JCO. 2006;(September):4293–4300
15. Boué F, Gabarre J, GaBarre J, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. JCO. 2006;(September):4123–4128
16. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. JCO. 2006;(July):3354–3360
17. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. JCO. 2006;(June):2502–2512
18. Jaffer AA, Lee FC, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. JCO. 2006;(February):663–667
19. Bouché O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803. JCO. 2004;(November):4319–4328
20. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. JCO. 2005;(February):792–799
21. Code of Federal Regulations. Title 21, part 54. Financial disclosure by clinical investigators.
22. Gwyther S, Bolis G, Gore M, et al. Experience with independent radiological review during a topotecan trial in ovarian cancer. Ann Oncol. 1997;8:463–468
    • MEDLINE
    • CrossRef
23. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. JCO. 2003;21(11):2059–2069
24. Hopper KD, Kasales CJ, Van Slyke MA, Schwartz TA, TenHave TR, Jozefiak JA. Analysis of interobserver and intraobserver variability in CT tumor measurements. Am J Roentgenol. 1996;167:851–854
25. FDA guidance for industry developing medical imaging drug and biologic products part three: design, analysis and interpretation of clinical studies; June 2004.
26. United States Food and Drug Administration Oncologic Drugs Advisory Committee briefing document for NDA 21-649 (oblimersen sodium).
27. United States Food and Drug Administration Oncologic Drugs Advisory Committee briefing document. BLA STN 125085/91.018 (bevacizumab); 5th December 2007.
28. US Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number 20-509/S029 (gemcitabine hydrochloride). Rockville, MD: US Department of Health and Human Services.
29. Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression free survival in phase III clinical trials: important design element or unnecessary expense?. JCO. 2008;26(22):3791–3796